SR9009 Results Timeline: What Studies Measured, and When

The short version: there is no published human timeline

Questions about "SR9009 results" usually assume a human dose–response curve exists — a point at which something measurable changes. In the published literature summarised on this page, it does not. Every finding below comes from mice, rats, or cultured cells. None of the cited work is a clinical trial in people, and none of it establishes a human onset interval, a human duration of effect, or a human endpoint of any kind.

What the animal literature does offer is a different kind of timeline, and arguably a more interesting one. SR9009 is an agonist at REV-ERB, a nuclear receptor embedded in the molecular circadian clock. Because of that, several published studies did not ask "how many weeks until an effect appears?" but rather "does the effect depend on when in the 24-hour cycle the compound was given?" Researchers reported a time-of-day dependent reduction in stroke infarct volume by the REV-ERB agonist SR9009 in mice (PMID 39557376), and a separate group reported a time-dependent effect of the REV-ERBα agonist SR9009 on nonalcoholic steatohepatitis and gut microbiota in mice (PMID 37161366). In both cases the clock position of dosing was itself a variable, not a footnote.

This page is for educational purposes only and is not medical advice; consult a licensed physician about any health decision. Nothing here describes a protocol, and no outcome described in an animal model should be read as an expected human result.

Three different "timescales" in the REV-ERB literature

The published work falls into roughly three measurement horizons. Grouping studies this way makes it clearer what each one could and could not detect.

1. Acute and single-insult models (hours)

The shortest-horizon studies measured tissue injury after an acute event. In the stroke model, the study reported that infarct volume reduction by SR9009 depended on the time of day at which mice were treated (PMID 39557376). A related line of cardiac work examined circadian PER2 as a therapeutic target in myocardial ischemia and reperfusion injury, again on the timescale of a single ischemic episode rather than weeks of treatment (PMID 34034593). These designs answer a narrow question — how much tissue was damaged — and say nothing about chronic use.

2. Repeated-dosing metabolic and inflammatory models (days to weeks)

A second group of studies gave the compound repeatedly and tracked metabolic or inflammatory readouts. Researchers reported that chronic low-dose REV-ERB agonist SR9009 mitigated constant light-induced weight gain and insulin resistance via adipogenesis modulation in an animal model (PMID 39800061). The liver work measured steatohepatitis severity alongside gut microbiota composition, and reported that the outcome varied with dosing time (PMID 37161366). In the airway, researchers reported that the molecular clock component REV-ERBα regulated cigarette smoke-induced pulmonary inflammation and epithelial–mesenchymal transition (PMID 34014841).

3. Disease-progression models (weeks to months)

The longest horizons appear in vascular and oncology models, where the endpoint is plaque burden or tumour growth rather than a single biomarker. A 2015 study reported suppression of atherosclerosis by a synthetic REV-ERB agonist (PMID 25800870). Separately, disrupting the core clock gene CLOCK was reported to lead to age-dependent cardiovascular disease — an effect that by definition only became visible as animals aged (PMID 28223222). That study did not test SR9009, but it illustrates why circadian endpoints are often slow to emerge.

What was measured, in what system

The oncology branch, and why it complicates "timeline" thinking

Several of the most-cited SR9009 papers are cancer-biology papers, not performance or metabolism papers. Researchers reported that SR9009 inhibited lethal prostate cancer subtype 1 by regulating the LXRα/FOXM1 pathway independently of REV-ERBs (PMID 36357378). That finding matters for any discussion of timing, because it indicates at least some of the compound's measured activity in that system did not run through the circadian receptor it was designed to hit. A timeline built on the assumption of clock-mediated action would not describe what was actually happening in that model.

A 2026 study reported that the REV-ERB agonist SR9009 potentiated sorafenib efficacy in liver cancer by targeting metabolic vulnerabilities (PMID 41554703) — a combination design, where the readout is the behaviour of two agents together rather than SR9009 alone. A 2025 review of new biochemical approaches for the treatment of glioblastoma situates clock-targeting chemistry within a broader set of experimental strategies for that tumour type (PMID 40983311). None of these are efficacy claims about healthy animals, and none are human results.

Why circadian timing often matters more than elapsed weeks

In most pharmacology, the question "how long until it works?" assumes accumulation: dose repeatedly, reach steady state, measure. Circadian pharmacology breaks that assumption, because the target oscillates. The same dose delivered twelve hours apart can land on a different point of the REV-ERB expression curve. That is precisely what the stroke study tested when researchers reported a time-of-day dependent reduction in infarct volume in mice (PMID 39557376), and what the liver study tested when it reported a time-dependent effect on steatohepatitis and gut microbiota (PMID 37161366).

The same principle appears outside the SR9009 literature. A 2024 study reported that nobiletin — a different compound entirely — promoted lipolysis of white adipose tissue in a circadian clock-dependent manner (PMID 39094217), reinforcing that clock-targeting molecules are frequently characterised by when rather than how long. REV-ERBα biology extends into immune cell behaviour as well: researchers reported that circadian rhythm-associated REV-ERBα modulated polarization of decidual macrophages via the PI3K/Akt signaling pathway (PMID 33934423).

What the published work does not establish

• No human onset interval. No clinical trial among these papers measured anything in people, so no "week 2" or "month 3" human milestone exists in this evidence base.
• No body-composition outcomes in humans. The weight and insulin-resistance findings were reported in a constant-light animal model of circadian disruption (PMID 39800061), which is not a model of ordinary human living.
• No exercise or endurance endpoints appear in the studies cited here; the measured endpoints were infarct volume (PMID 39557376), liver pathology (PMID 37161366), vascular lesions (PMID 25800870) and tumour biology (PMID 36357378).
• No consistent mechanism. At least one study reported activity independent of REV-ERBs (PMID 36357378), which means off-target contributions cannot be excluded.

SR9009 Adverse Events: What Studies Report

The papers summarised here were designed around disease endpoints rather than systematic safety surveillance, and none of them is a human safety study. The liver-focused study reported effects on steatohepatitis and gut microbiota composition that varied by dosing time in mice (PMID 37161366) — a reminder that hepatic and microbial systems were measurably altered, in both directions depending on the design. The metabolic study reported changes in adipogenesis in an animal model (PMID 39800061), and the oncology study reported pathway-level activity through LXRα/FOXM1 that did not require REV-ERBs (PMID 36357378). Because no clinical trial appears in this evidence set, no human adverse-event profile, frequency or threshold can be described from it.

How to read any SR9009 "timeline" claim

1. Check the species. If the source does not name one, it is almost certainly extrapolating from mice.
2. Check whether dosing time was controlled. Two of the clearest findings here were explicitly time-of-day dependent (PMID 39557376, PMID 37161366).
3. Check the endpoint. Infarct volume, plaque area and tumour inhibition are not interchangeable with subjective human outcomes (PMID 25800870).
4. Check whether the compound was given alone. The liver cancer work was a combination study with sorafenib (PMID 41554703).

Regulatory status is worth stating plainly: SR9009 is a research chemical. It is not an approved medicine in the United States, and the literature described above is preclinical research, not evidence of safe or effective human use.

References

• Time of day dependent reduction in stroke infarct volume by the Reverb agonist SR9009 in mice (Experimental Neurology, 2025)
• Time-dependent effect of REV-ERBα agonist SR9009 on nonalcoholic steatohepatitis and gut microbiota in mice (Chronobiology International, 2023)
• Chronic low-dose REV-ERBs agonist SR9009 mitigates constant light-induced weight gain and insulin resistance via adipogenesis modulation (Biomedical Journal, 2025)
• Suppression of atherosclerosis by synthetic REV-ERB agonist (Biochemical and Biophysical Research Communications, 2015)
• SR9009 inhibits lethal prostate cancer subtype 1 by regulating the LXRα/FOXM1 pathway independently of REV-ERBs (Cell Death & Disease, 2022)
• Targeting metabolic vulnerabilities: REV-ERB agonist SR9009 potentiates sorafenib efficacy in liver cancer (Cell Death Discovery, 2026)
• Molecular clock REV-ERBα regulates cigarette smoke-induced pulmonary inflammation and epithelial-mesenchymal transition (JCI Insight, 2021)
• Targeting circadian PER2 as therapy in myocardial ischemia and reperfusion injury (Chronobiology International, 2021)
• Disrupting the key circadian regulator CLOCK leads to age-dependent cardiovascular disease (Journal of Molecular and Cellular Cardiology, 2017)
• Circadian rhythm-associated Rev-erbα modulates polarization of decidual macrophage via the PI3K/Akt signaling pathway (American Journal of Reproductive Immunology, 2021)
• Nobiletin promotes lipolysis of white adipose tissue in a circadian clock-dependent manner (The Journal of Nutritional Biochemistry, 2024)
• New biochemical approaches for the treatment of glioblastoma (The Journal of Biological Chemistry, 2025)